Skip to main content

Reproductive Health Science Inks PGS Distribution Deal with Tani Medikal

NEW YORK (GenomeWeb) – Australian biotech firm Reproductive Health Science said that it has signed a three-year exclusive agreement with Tani Medikal for the distribution of RHS's EmbryoCellect kit for pre-implantation genetic screening for in vitro fertilization.

Tani Medikal is based in Turkey and will distribute EmbryoCellect in Turkey, Azerbaijan, Georgia, Turkish Republic of Northern Cyprus, Kosovo, Macedonia, and North Iraq (Kurdish region).

EmbryoSelect uses microarray-based comparative genomic hybridization to compare the number of chromosomes in a sample cell to a known reference sample, providing a way to count the number of chromosomes in the test cell and detect whole chromosome aneuploidy.

Adelaide-based RHS went public in April after raising A$3 million (US$2.8 million at the time) and completing a reverse merger with AO Energy, a publicly traded mining company.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.